Medlab Clinical Limited (MDC:ASX)

16.0¢

right-arrow Created with Sketch. 0.005 (3.23%)
MCAP $54.74M
Last trade 15.59pm 20/10/2021 20mins delayed

Latest Announcements

20/10/2021MDCMedlab Clinical Limited
20/10/2021 Price SensitivePSMDCMedlab Clinical Limited
13/10/2021MDCMedlab Clinical Limited
1,411
MCap
13/10/2021MDCMedlab Clinical Limited
13/10/2021MDCMedlab Clinical Limited
203
MCap
08/10/2021 Price SensitivePSMDCMedlab Clinical Limited
06/10/2021 Price SensitivePSMDCMedlab Clinical Limited
14/09/2021MDCMedlab Clinical Limited

Company Overview

Medlab Clinical Limited is an Australian biotechnology company. The Company operates through two segments: Nutraceutical and Pharmaceutical Research. The Nutraceutical segment is engaged in the supply of Medlab’s self-branded nutraceutical range, predominantly in Australia. The Pharmaceutical Research segment is engaged in research activities, which includes depression and oncology, and the supply of cannabis-based medicines. Its pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The Company's lead candidate is NanaBis, which targets for the treatment of bone pain in breast and prostate cancer patients. Its NanoCelle is designed to address known medication problems and addressing global unmet medical needs. The Company's products include NanaBidial, NanoCBD, and MgOptima and CBD.

MDC in the news

Medlab Clinical (MDC) sells the Australian-only part of its nutraceutical business to…
Medlab Clinical’s (MDC) proprietary delivery platform NanoCell receives a Notice of Allowance…
Medlab Clinical (MDC) receives a notice of allowance from the United States…
Medlab Clinical (MDC) receives human ethics approval for Australian sites for its…

Search Previous Announcements